Anti-ITM2B antibody

Supplementary info

Activity summary

ITM2B also known as Integral Membrane Protein 2B or BRI2 is a transmembrane protein weighing approximately 30 kDa. This protein is expressed widely in human tissues showing particularly high levels in the central nervous system and brain. ITM2B functions mechanically by playing a role in protein processing and trafficking owing to its transmembrane nature. With an integral role in cellular functions ITM2B interacts with various cellular components associated with membrane-related activities.

Biological function summary

ITM2B engages in several vital cellular processes such as regulation of amyloid precursor protein (APP) processing. ITM2B forms part of a complex with other proteins involved in APP cleavage which is significant for maintaining cell homeostasis. It also influences neuronal functions through its effects on synaptic plasticity and could impact cognitive abilities. The protein's presence in brain regions ties ITM2B closely to neural activities where protein interactions are essential for cellular communication.

Pathways

ITM2B exerts influence on critical processes in amyloidogenic pathways contributing to the modulation of amyloid-beta production. This protein directly interacts with other players like APP and presenilin 1 within this pathway affecting the levels of amyloids and ultimately impacting neural integrity. Additionally ITM2B participates in Wnt signaling pathways linking it to cellular differentiation and proliferation where it modulates interactions with proteins that convey Wnt signals such as beta-catenin.

Associated diseases and disorders

ITM2B is directly linked to familial British dementia and familial Danish dementia both neurodegenerative conditions. These diseases involve mutations in the ITM2B gene leading to abnormal protein aggregates that disrupt normal brain function. ITM2B's relationship with amyloid-beta and presenilin 1 also connects it to Alzheimer's disease pathogenesis where these proteins play roles in amyloid plaque formation a hallmark of Alzheimer's. Studies focus on targeting ITM2B interactions and processing to develop therapies for these conditions highlighting its potential as a therapeutic target.